Association of hyperuricemia and hypertension phenotypes in hypertensive patients without uric acid lowering treatment

References

• Whelton PK, Carey RM, Aronow WS, Casey DE Jr., Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a Report of the American college of cardiology/American heart association task force on clinical practice guidelines. Hypertension. 2018;71:e13–e115. doi:10.1161/HYP.0000000000000065.
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, De Simone G, Dominiczak A, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–104.
   PubMed Web of Science ®Google Scholar
• 2018 Chinese Guidelines for Prevention and Treatment of hypertension-a report of the revision committee of chinese guidelines for prevention and treatment of hypertension. J Geriatric Cardiol 2019;16(182–241).
   Google Scholar
• He J, Gu D, Wu X, Reynolds K, Duan X, Yao C, Wang J, Chen CS, Chen J, Wildman RP, et al. Major causes of death among men and women in China. N Engl J Med. 2005;353:1124–34. doi:10.1056/NEJMsa050467.
   PubMed Web of Science ®Google Scholar
• Wang Z, Chen Z, Zhang L, Wang X, Hao G, Zhang Z, Shao L, Tian Y, Dong Y, Zheng C, et al. Status of hypertension in China: results from the China hypertension survey, 2012-2015. Circulation. 2018;137:2344–56. doi:10.1161/CIRCULATIONAHA.117.032380.
   PubMed Web of Science ®Google Scholar
• Lu J, Lu Y, Wang X, Li X, Linderman GC, Wu C, Cheng X, Mu L, Zhang H, Liu J, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1·7 million adults in a population-based screening study (China PEACE Million persons project). Lancet. 2017;390:2549–58. doi:10.1016/S0140-6736(17)32478-9.
   PubMed Web of Science ®Google Scholar
• Perlstein TS, Gumieniak O, Williams GH, Sparrow D, Vokonas PS, Gaziano M, Weiss ST and Litonjua AA. Uric acid and the development of hypertension: the normative aging study. Hypertension. 2006;48:1031–36. doi:10.1161/01.HYP.0000248752.08807.4c.
   PubMed Web of Science ®Google Scholar
• Krupp D, Esche J, Mensink GB, Neuhauser HK, Remer T. Diet-independent relevance of serum uric acid for blood pressure in a representative population sample. J Clin Hypertens. 2017;19:1042–50. doi:10.1111/jch.13046.
   Web of Science ®Google Scholar
• Zupo R, Castellana F, Boninfante B, Lampignano L, Lattanzio A, Sardone R, Giannelli G, De Pergola G.Uric acid and potassium serum levels are independent predictors of blood pressure non-dipping in overweight or obese subjects. Nutrients. 2019;11(12):2970. doi:10.3390/nu11122970.
   PubMed Web of Science ®Google Scholar
• Wang Y, Hu JW, Lv YB, Chu C, Wang KK, Zheng WL, Cao YM, Yuan ZY, Mu JJ. The role of uric acid in hypertension of adolescents, prehypertension and salt sensitivity of blood pressure. Med Sci Monit. 2017;23:790–95. doi:10.12659/MSM.899563.
   PubMed Web of Science ®Google Scholar
• Qin T, Zhou X, Wang J, Wu X, Li Y, Wang L, Huang H, Li J. Hyperuricemia and the prognosis of hypertensive patients: a systematic review and meta-analysis. J Clin Hypertens. 2016;18:1268–78. doi:10.1111/jch.12855.
   Web of Science ®Google Scholar
• Gunawardhana L, McLean L, Punzi HA, Hunt B, Palmer RN, Whelton A, Feig DI. Effect of febuxostat on ambulatory blood pressure in subjects with hyperuricemia and hypertension: a phase 2 randomized placebo-controlled study. J Am Heart Assoc. 2017;6. doi:10.1161/JAHA.117.006683.
   PubMed Web of Science ®Google Scholar
• Agarwal V, Hans N, Messerli FH. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J Clin Hypertens. 2013;15:435–42. doi:10.1111/j.1751-7176.2012.00701.x.
   PubMed Web of Science ®Google Scholar
• Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. Jama. 2008;300:924–32. doi:10.1001/jama.300.8.924.
   PubMed Web of Science ®Google Scholar
• Kojima S, Matsui K, Hiramitsu S, Hisatome I, Waki M, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Jinnouchi H, et al. Febuxostat for cerebral and cardiorenovascular events PrEvEntion StuDy. Eur Heart J. 2019;40:1778–86. doi:10.1093/eurheartj/ehz119.
   PubMed Web of Science ®Google Scholar
• Goicoechea M, Garcia De Vinuesa S, Verdalles U, Verde E, Macias N, Santos A, Pérez De Jose A, Cedeño S, Linares T, Luño J. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. Am J Kidney Dis. 2015;65:543–49. doi:10.1053/j.ajkd.2014.11.016.
   PubMed Web of Science ®Google Scholar
• Liu P, Chen Y, Wang B, Zhang F, Wang D and Wang Y. Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallel-controlled study. Clin Endocrinol (Oxf). 2015;83:475–82. doi:10.1111/cen.12673.
   PubMed Web of Science ®Google Scholar
• Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Chatterjee S and Pandey R. Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis. 2015;66:945–50. doi:10.1053/j.ajkd.2015.05.017.
   PubMed Web of Science ®Google Scholar
• Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, Ito S, Yamamoto T, Tomino Y, Ohno I, et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis. 2018;72:798–810. doi:10.1053/j.ajkd.2018.06.028.
   PubMed Web of Science ®Google Scholar
• Badve SV, Pascoe EM, Tiku A, Boudville N, Brown FG, Cass A, Clarke P, Dalbeth N, Day RO, De Zoysa JR, et al. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med. 2020;382:2504–13. doi:10.1056/NEJMoa1915833.
   PubMed Web of Science ®Google Scholar
• Kario K, Park S, Chia YC, Sukonthasarn A, Turana Y, Shin J, Chen CH, Buranakitjaroen P, Divinagracia R, Nailes J, et al. 2020 Consensus summary on the management of hypertension in Asia from the HOPE Asia network. J Clin Hypertens. 2020;22:351–62. doi:10.1111/jch.13751.
   Web of Science ®Google Scholar
• Kario K, Shin J, Chen CH, Buranakitjaroen P, Chia YC, Divinagracia R, Nailes J, Hoshide S, Siddique S, Sison J, et al. Expert panel consensus recommendations for ambulatory blood pressure monitoring in Asia: the HOPE Asia Network. J Clin Hypertens. 2019;21:1250–83. doi:10.1111/jch.13652.
   PubMed Web of Science ®Google Scholar
• Zhang DY, Guo QH, An DW, Li Y, Wang JG. A comparative meta-analysis of prospective observational studies on masked hypertension and masked uncontrolled hypertension defined by ambulatory and home blood pressure. J Hypertens. 2019;37:1775–85. doi:10.1097/HJH.0000000000002109.
   PubMed Web of Science ®Google Scholar
• Grassi G, Mancia G. Masked uncontrolled hypertension. Hypertension. 2019;73:39–41. doi:10.1161/HYPERTENSIONAHA.118.12050.
   PubMedGoogle Scholar
• Parati G, Agabiti-Rosei E, Bakris GL, Bilo G, Branzi G, Cecchi F, Chrostowska M, De La Sierra A, Domenech M, Dorobantu M, et al. MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol. BMJ Open. 2018;8:e021038. doi:10.1136/bmjopen-2017-021038.
   PubMed Web of Science ®Google Scholar
• Pierdomenico SD, Pierdomenico AM, Coccina F, Clement DL, De Buyzere ML, De Bacquer DA, Ben-Dov IZ, Vongpatanasin W, Banegas JR, Ruilope LM, et al. Prognostic Value of masked uncontrolled hypertension. Hypertension. 2018;72:862–69. doi:10.1161/HYPERTENSIONAHA.118.11499.
   PubMed Web of Science ®Google Scholar
• Margolis KL, Asche SE, Dehmer SP, Bergdall AR, Green BB, Sperl-Hillen JM, Nyboer RA, Pawloski PA, Maciosek MV, Trower NK, et al. Long-term outcomes of the effects of home blood pressure telemonitoring and pharmacist management on blood pressure among adults with uncontrolled hypertension: follow-up of a cluster randomized clinical trial. JAMA Network Open. 2018;1:e181617. doi:10.1001/jamanetworkopen.2018.1617.
   PubMed Web of Science ®Google Scholar
• Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension. 2003;42:247–52. doi:10.1161/01.HYP.0000085858.66548.59.
   PubMed Web of Science ®Google Scholar
• Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–63. doi:10.1016/S0140-6736(03)15268-3.
   PubMed Web of Science ®Google Scholar
• Collard D, Brouwer TF, Olde Engberink RHG, Zwinderman AH, Vogt L, Van Den Born BH. Initial estimated glomerular filtration rate decline and long-term renal function during intensive antihypertensive therapy: a post hoc analysis of the SPRINT and ACCORD-BP randomized controlled trials. Hypertension 2020;75:1205–12. Hypertensionaha11914659. doi:10.1161/HYPERTENSIONAHA.119.14659.
   PubMed Web of Science ®Google Scholar
• Sanchez-Lozada LG, Rodriguez-Iturbe B, Kelley EE, Nakagawa T, Madero M, Feig DI, Borghi C, Piani F, Cara-Fuentes G, Bjornstad P, et al. Uric acid and hypertension: an update with recommendations. Am J Hypertens. 2020;33:583–94. doi:10.1093/ajh/hpaa044.
   PubMed Web of Science ®Google Scholar
• Domènech M, Serra-Mir M, Roth I, Freitas-Simoes T, Valls-Pedret C, Cofán M, López A, Sala-Vila A, Calvo C, Rajaram S, et al. Effect of a walnut diet on office and 24-hour ambulatory blood pressure in elderly individuals. Hypertension. 2019;73:1049–57. doi:10.1161/HYPERTENSIONAHA.118.12766.
   PubMed Web of Science ®Google Scholar
• Feig DI. Uric acid and hypertension. Semin Nephrol. 2011;31:441–46. doi:10.1016/j.semnephrol.2011.08.008.
   PubMed Web of Science ®Google Scholar
• Wang J, Qin T, Chen J, Li Y, Wang L, Huang H, Li J. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PloS One. 2014;9:e114259. doi:10.1371/journal.pone.0114259.
   PubMed Web of Science ®Google Scholar
• Kansui Y, Matsumura K, Morinaga Y, Inoue M, Kiyohara K, Ohta Y, Goto K, Ohtsubo T, Ooboshi H and Kitazono T. Impact of serum uric acid on incident hypertension in a worksite population of Japanese men. J Hypertens. 2018;36:1499–505. doi:10.1097/HJH.0000000000001743.
   PubMedGoogle Scholar
• Scheepers L, Boonen A, Dagnelie PC, Schram MT, Van Der Kallen CJH, Henry RMA, Kroon AA, Stehouwer CDA, Arts ICW. Uric acid and blood pressure: exploring the role of uric acid production in the Maastricht Study. J Hypertens. 2017;35:1968–75. doi:10.1097/HJH.0000000000001417.
   PubMed Web of Science ®Google Scholar
• Kuwabara M, Hisatome I, Niwa K, Hara S, Roncal-Jimenez CA, Bjornstad P, Nakagawa T, Andres-Hernando A, Sato Y, Jensen T, et al. Uric acid is a strong risk marker for developing hypertension from prehypertension: a 5-year Japanese cohort study. Hypertension. 2018;71:78–86. doi:10.1161/HYPERTENSIONAHA.117.10370.
   PubMed Web of Science ®Google Scholar
• Zhang JX, Zhang YP, Wu QN, Chen B. Uric acid induces oxidative stress via an activation of the renin-angiotensin system in 3T3-L1 adipocytes. Endocrine. 2015;48:135–42. doi:10.1007/s12020-014-0239-5.
   PubMed Web of Science ®Google Scholar
• Maruhashi T, Hisatome I, Kihara Y, Higashi Y. Hyperuricemia and endothelial function: from molecular background to clinical perspectives. Atherosclerosis. 2018;278:226–31. doi:10.1016/j.atherosclerosis.2018.10.007.
   PubMed Web of Science ®Google Scholar
• Kimura Y, Yanagida T, Onda A, Tsukui D, Hosoyamada M, Kono H. Soluble uric acid promotes atherosclerosis via AMPK (AMP-Activated Protein Kinase)-mediated inflammation. Arterioscler Thromb Vasc Biol. 2020;40:570–82. doi:10.1161/ATVBAHA.119.313224.
   PubMed Web of Science ®Google Scholar
• Martinon F, Pétrilli V, Mayor A, Tardivel A and Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237–41. doi:10.1038/nature04516.
   PubMed Web of Science ®Google Scholar
• Afsar B, Elsurer R, Ozdemir FN, Sezer S. Uric acid and nocturnal nondipping in hypertensive patients with normal renal function. J Nephrol. 2008;21:406–11.
   PubMed Web of Science ®Google Scholar
• Turak O, Ozcan F, Tok D, Işleyen A, Sökmen E, Taşoğlu I, Aydoğdu S, Sen N, McFann K, Johnson RJ, et al. Serum uric acid, inflammation, and nondipping circadian pattern in essential hypertension. J Clin Hypertens. 2013;15:7–13. doi:10.1111/jch.12026.
   PubMed Web of Science ®Google Scholar
• Tutal E, Sayın B, Ertugrul DT, Ibis A, Sezer S, Ozdemir N. Is there a link between hyperuricemia, morning blood pressure surge, and non-dipping blood pressure pattern in metabolic syndrome patients? Int J Nephrol Renovasc Dis. 2013;6:71–77. doi:10.2147/IJNRD.S41384.
   PubMedGoogle Scholar